Increasing Prevalence of Metabolic Disorders to Reflect Positively on European Metabolic Disorder Therapeutics Market

European metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.4% during the forecast period. The increasing prevalence of metabolic disorders such as diabetes and obesity is accelerating market growth. As per the Organization for Economic Cooperation and Development (OECD), since 2000, obesity has increased in nearly all European countries. As per the European Union (EU), obesity and weight problems are increasing rapidly in most EU member states, with 51.6 % of the EU’s population (18 and above) overweight in 2014. In women, the highest proportions of the obese population were observed in Malta, Latvia, Estonia, and UK, with 23.9%, 23.3%, 21.5%, and 20.4%, respectively in 2014. 

Browse the full report description European Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/european-metabolic-disorder-therapeutics-market

Obesity, overweight, and the metabolic syndrome have emerged as risk factors for end-stage renal disease (ESRD) and chronic kidney disease (CKD). Therefore, a potential treatment of obesity has emerged in Europe to prevent the occurrence of severe conditions. Drugs that are used for the treatment of obesity include Orlistat (Xenical) and Phentermine. Orlistat (Xenical) works by reducing fat absorption by nearly 30%. With the emerging incidences of obesity, more therapies of obesity treatment are expected to increase, which in turn, will offer an opportunity for market growth.

Scope of the European Metabolic Disorder Therapeutics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Therapy and Disease
• Regions Covered- UK, Germany, France, Spain, Italy, and Rest of Europe
• Competitive Landscape- Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, and AstraZeneca plc.

Recent Strategic Initiatives in the European Metabolic Disorder Therapeutics Market

• In March 2020, AstraZeneca plc declared the collaboration with Silence Therapeutics for discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics to treat CVD, respiratory, renal, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung. 
• In March 2020, Eli Lilly and Co. declared the global licensing and research partnership with Sitryx, a biopharmaceutical company engaged in the development of therapeutics in immuno-inflammation and immuno-oncology. Under the partnership, the companies will study up to four new preclinical targets that are identified by Sitryx that could result in potential new medicines for autoimmune diseases. Lilly will make a $10 million equity investment in Sitryx and Sitryx will get an upfront payment of $50 million.

Key questions addressed by the report

• What is the market growth rate?
• Which segment/country dominates the market in the base year?
• Which segment/country will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

European Metabolic Disorder Therapeutics Market-Segmentation

By Therapy

• Drug Therapy
• Gene Therapy
• Cellular Transplantation
• Enzyme Replacement Therapy
• Others

By Disease

• Obesity
• Diabetes
• Lysosomal Storage Disease
• Hypercholesterolemia
• Others

European Metabolic Disorder Therapeutics Market– Segment by Country

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe